Therapeutic Advances in Hematology
Share

Therapeutic Advances in Hematology


Managing Editor
Alessandro Baliani SAGE Publications Ltd, London, UK
Associate Editors
Elias Jabbour M.D. Anderson Cancer Center, Houston, TX, USA
Michaela Liedtke Stanford Cancer Institute, Stanford, CA, USA
Michael Mauro Memorial Sloan-Kettering Cancer Center, New York, NY, USA
John Sweetenham Huntsman Cancer Institute, University of Utah, UT, USA

Other Titles in:
Hematologic Disorders | Hematology

eISSN: 20406215 | ISSN: 20406207 | Current volume: 8 | Current issue: 3 Frequency: Bi-monthly

Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. You can access the journal online for free at www.sagepub.com/tah.

The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of hematology, including all of the malignant myeloid and lymphoid disorders (leukemia, myeloproliferative disorders, myelodysplasia, lymphoma, myeloma, etc), red cell and platelet disorders, including transfusion medicine and clotting disorders, and any other relevant topic in the field.

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

Unofficial impact factor for 2014, based on Thomson Reuters Web of Science®: 2.11

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:
Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email: reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE).

The journal is for all professionals concerned with research into, and the practice of hematology and is a forum for publishing original research and reviews in this area. The editors welcome articles of current interest on research across all areas of hematology, including acute and chronic myeloid leukemia, myelodysplasia, myeloma, lymphoma and clotting disorders.

Topics will include:

·Novel approaches and management of Hodking Lymphoma

·Novel therapy in myelofibrosis

·First-line treatment in peripheral T-cell lymphomas

·Rapid identification of therapeutic targets in hematologic malignancies via functional genomics

·LNK dysfunction in mice, men, and myeloproliferative neoplasms

·Advances in treatment of follicular lymphoma

·Role of microRNAs in hematopoietic stem cell and leukemia stem cell function

·Treatment options for high-risk CLL

Editorial Board
Mark Alderson Path, Seattle, USA
Jorge Cortes M.D. Anderson Cancer Center, Houston, TX, USA
Myron Czuczman Roswell Park Cancer Institute, Buffalo, NY, USA
Elliot Epner Penn State Hershey Cancer Institute, Hershey, PA, USA
Elihu Estey Seattle Cancer Center Alliance, Seattle, WA, USA
Stefan Faderl M.D. Anderson Cancer Center, Houston, TX, USA
Ian Feavers National Institute of Biological Standards and Control, Potters Bar, UK
Alessandra Ferrajoli M.D. Anderson Cancer Center, Houston, TX, USA
Patrick Fogarty University of Pennsylvania, Philadelphia, PA, USA
Guillermo Garcia-Manero M.D. Anderson Cancer Center, Houston, TX, USA
Amy Geddis Moores Cancer Center, San Diego, CA, USA
Terry Gernsheimer Puget Sound Blood Center, Seattle, CA, USA
Katharina Gotze Technical University of Munich, Munich, Germany
Eric Grabowski Yawkey Center, Boston MA, USA
Elizabeth Hexner University of Pennsylvania, Philadelphia, PA, USA
Lance Jennings Canterbury Health Laboratories, Christchurch, New Zealand
Ulrich Keller Technical University of Munich, Munich, Germany
Maya Koren-Michowitz Sheba Medical Center, Tel Hashomer, Israel
Karl-Anton Kreuzer University of Cologne, Germany
Hillard Lazarus Case Western Reserve University, Cleveland, OH, USA
Georg Lenz Charite - University Medicine Berlin, Berlin, Germany
Howard Liebman University of Southern California - Keck School of Medicine, Los Angeles, CA, USA
Eduardo Olavarria López Hospital de Navarra, Pamplona, Spain
Keith McCrae Lerner Research Institute, Cleveland, OH, USA
Stephen Oh Washington University School of Medicine, St. Louis, MO, USA
Bipin Savani Vanderbilt University Medical Center, Nashville, TN, USA
Deborah Thomas M.D. Anderson Cancer Center, Houston, TX, USA
Peter Valent Medical University of Vienna, Vienna, Austria
Alessandro Vannucchi University of Florence, Florence, Italy
Nikolas von Bubnoff Technical University of Munich, Munich, Germany
Guy Young University of Southern California-Keck School of Medicine, Los Angeles, CA, USA
  • Chemical Abstracts Service (CAS)
  • Medscape
  • PubMed
  • Unofficial impact factor for 2014, based on citation data from Thomson Reuters Web of Science®: 2.11
    1. Article types
    2. Editorial Policies
      2.1 Peer review policy
      2.2 Authorship
      2.3 Acknowledgements
      2.3.1 Writing Assistance
      2.4 Funding
      2.5 Declaration of conflicting interests
      2.6 Research ethics and patient consent
      2.7 Clinical Trials
      2.8 Reporting Guidelines
      2.9 Data
    3. Publishing Policies
      3.1 Publication Ethics
      3.1.1 Plagiarism
      3.1.2 Prior to publication
      3.2 Contributor's publishing agreement
      3.3 Open Access and author archiving
      3.4 Permissions
    4. Preparing your manuscript
      4.1 Word processing formats
      4.2 Artwork, figures and other graphics
      4.3 Supplementary material 
      4.4 Journal layout
      4.5 Reference style
      4.6 English language editing services
    5. Submitting your manuscript
      5.1 How to submit your manuscript
      5.2 Title, keywords and abstracts
      5.3 Corresponding author contact details
    6. On acceptance and publication
      6.1 SAGE Production
      6.2 Access to your published article
      6.3 Online First publication
    7. Further Information

    This Journal is a member of the Committee on Publication Ethics This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE)

    All articles are listed on PubMed.

    Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal can be accessed online without charge at http://tah.sagepub.com.

    Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/tah to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Hematology will be reviewed. As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    Back to top

    1. Article types

    Therapeutic Advances in Hematology considers the following kinds of article for publication:
    1. Original Research Articles, describing new experimental findings, or analyses (e.g. posthoc, subgroup, meta-analysis where an overall statistic is derived).
    2. Review Articles. The Editors wish to encourage the following types of review, but request that authors contact them in advance:
    (a) general reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
    (b) perspectives - brief overviews, which are 6-8 printed pages in length including references, that address important new areas of general interest;
    (c) systematic reviews and meta-analyses - these should be reported according to the PRISMA reporting guidelines (please see section 2.8);
    (d) critiques - focused and provocative reviews that are followed by a number of invited commentaries, with a concluding reply from the main author;
    (e) structured case reports - outlining an interesting case, and including a full review of the pertinent literature and a section on implications for clinical care;
    (f) case series studies or clinical series – descriptive study of a small group of patients (with the same disease or receiving the same treatment) including a full review of the pertinent literature and a section on implications for clinical care;
    3. Letters to the Editor; these also include brief case reports. These should be as concise as possible and up to 1000 words.

    The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Hematology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.

    Back to top

    2. Editorial Policies

    2.1 Peer review policy

    The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Hematology operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author.  Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations.  All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.

    As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

    • The reviewer should have no prior knowledge of your submission
    • The reviewer should not have recently collaborated with any of the authors
    • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    2.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors. The list of authors should include all those who can legitimately claim authorship. This is all those who:

    1. Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
    2. Drafted the article or revised it critically for important intellectual content,
    3. Approved the version to be published,
    4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    2.3 Acknowledgments

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Between the end of the main text and the start of the references section, please acknowledge sources of financial and material support, and those who have contributed intellectually, with their consent. Please see guidelines for: Funding Acknowledgement

    2.3.1 Writing Assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    2.4 Funding

    Therapeutic Advances in Hematology requires all Authors to acknowledge their funding in a consistent fashion under a separate heading.  requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

    2.5 Declaration of conflicting interests

    It is the policy of the Therapeutic Advances series to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.   

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.    

    For guidance on conflict of interest statements, please see the ICMJE recommendations here

    2.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived the need for) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal. Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must have been approved by an Ethics Committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    2.7 Clinical Trials

    Therapeutic Advances in Hematology endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and the registration number must be included at the end of the abstract.

    2.8 Reporting Guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. All randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure, and a completed CONSORT checklist as a supplementary file. Systematic reviews and meta-analyses should be reported according to the PRISMA reporting guidelines; please ensure that you submit a completed flow diagram as a cited figure, and a completed PRISMA checklist as a supplementary file.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    2.9 Data

    SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

    Therapeutic Advances in Hematology requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at tah@sagepub.co.uk.

    Back to top

    3. Publishing Policies

    3.1 Publication Ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway

    3.1.1 Plagiarism

    Therapeutic Advances in Hematology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    3.2 Contributor's publishing agreement

    Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.

    3.3 Open Access and author archiving

    Therapeutic Advances in Hematology offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.

    3.4 Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway

    Back to top

    4. Preparing your manuscript

    4.1 Word processing formats

    Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    4.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines 

    4.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article.  For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.

    4.4 Journal layout

    The journal conforms to the SAGE house style. View the SAGE UK House Style guidelines.

    4.5 Reference style

    Therapeutic Advances in Hematology adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

    If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.

    EndNote: here
    Zotero: here

    Examples of References:

    Journal citations:
    1. Ludbrook J, Miller T and Russel A. Musculovenous pumps in the human lower limb. Am Heart J 1966; 71: 635–641.
    2. Araki C, Black TL, Patberg FT, et al. Significance of calf muscle pump function in venous ulceration. J Vasc Surg 1994; 20: 872–879.

    Chapter in book
    1. Huff D and Black TL. Comprehensive statistics. In: Miller C and Smith H (eds) How to lie with statistics. 4th ed. London: Penguin, 1991, pp.51–55.

    4.6 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    5. Submitting your manuscript

    5.1 How to submit your manuscript

    Therapeutic Advances in Hematology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tah to login and submit your article online. IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    5.2 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online

    Abstract - The abstract should accurately and concisely reflect the content of the article, and should be limited to 300 words. Original research articles should include structured abstracts, using the four headings Objectives, Methods, Results, and Conclusions. Please avoid reference citations and undefined abbreviations in the abstract.   Review articles do not require structured abstracts.
    Key words (or key word phrases) 2-8 to accompany the abstract. They should, if possible, be drawn from the MeSH list of Index Medicus and be chosen with a view to useful cross-indexing of the article.  
    Main text - Subdivide your article with appropriate headings. Use no more than two levels of subheadings. 

    5.3 Corresponding author contact details

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

    Back to top

    6. On acceptance and publication

    6.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.

    6.2 Access to your published article

    SAGE provides authors with online access to their final article.

    6.3 Online First publication

    Online First allows final revision articles (completed articles in queue for assignment to an upcoming issue) to be published online prior to their inclusion in a final journal issue which significantly reduces the lead time between submission and publication. For more information please visit our Online First Fact Sheet

    Back to top

    7. Further Information

    Any correspondence, queries or additional requests for information should be sent to the editorial office at tah@sagepub.co.uk.

    For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

    Commercial Sales Team, London, UK
    Tel: +44 20 7336 1205
    Email: reprints@sagepub.co.uk

    Back to top

    Individual Subscription, E-access


    Institutional Subscription, E-access